Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | PTPN7 | P35236 | 3/20 | 0.32 |
| ▸ | HMGCR | P04035 | 1/20 | 0.32 |
| ▸ | MIF | P14174 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18804001 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL10551777 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL29726945 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL11069629 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL4524706 | 1.00 | — | — | |
| SCHEMBL9717348 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL1524410 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL2705613 | 1.00 | ALDH1A1 (0.41) | ALDH1A1LMNAHSD17B10MEN1KMT2A | |
| SCHEMBL1141520 | 0.97 | — | — | |
| SCHEMBL1524228 | 0.89 | TSHR (0.42) | ALDH1A1LMNAHSD17B10MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58062103-A | — | — | None | — | — | JP | disclosed |
| US-12622891-B2 | AMP-activated protein kinase activator | KYOTO PHARMACEUTICAL UNIVERSITY (JP) | 2026-05-12 | — | — | US | disclosed |
| US-20240277657-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | KYOTO PHARMACEUTICAL UNIVERSITY (JP) | 2024-08-22 | — | — | US | disclosed |
| EP-4349331-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | Kyoto Pharmaceutical University (JP) | 2024-04-10 | — | — | EP | disclosed |
| CN-117794527-A | Novel AMP-activating protein kinase activators | 学校法人京都药科大学 | 2024-03-29 | — | — | CN | disclosed |
| WO-2022255499-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | 学校法人京都薬科大学 | 2022-12-08 | — | — | WO | disclosed |
| US-11407726-B2 | Using stereoretention for the stereoselective formation of e-macrocycles with Ru-based olefin metathesis catalysts | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2022-08-09 | — | — | US | disclosed |
| US-11365183-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2022-06-21 | — | — | US | disclosed |
| US-20200385360-A1 | USING STEREORETENTION FOR THE STEREOSELECTIVE FORMATION OF E-MACROCYCLES WITH RU-BASED OLEFIN METATHESIS CATALYSTS | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2020-12-10 | — | — | US | disclosed |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2019-10-17 | — | — | US | disclosed |
| EP-3222612-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2017-09-27 | — | — | EP | disclosed |
| EP-2376432-B1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (MDC) (DE) | 2017-04-12 | — | — | EP | disclosed |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (DE) | 2016-11-10 | — | — | US | disclosed |
| US-9272991-B2 | Eicosanoid derivatives | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2016-03-01 | — | — | US | disclosed |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | MAX-DELBRUECK-CENTRUM FUER MOLEKULARE MEDIZIN (MDC) (DE) | 2012-05-17 | — | — | US | disclosed |
| EP-2376432-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010081683-A1 | NOVEL EICOSANOID DERIVATIVES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2010-07-22 | — | — | WO | disclosed |
| EP-2208720-A1 | Novel eicosanoid derivatives | Max-Delbrück-Centrum für Molekulare Medizin (MDC) (DE) | 2010-07-21 | — | — | EP | disclosed |
| US-5236900-A | Treating Candida infections | SCHERING CORPORATION (US) | 1993-08-17 | — | — | US | disclosed |
| JP-S5862103-A | SEXUAL ATTRACTANT FOR DICHOCROCIS PUNCTIFERALIS | MATSUMOTO YOSHIAKI | 1983-04-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200385360-A1 | USING STEREORETENTION FOR THE STEREOSELECTIVE FORMATION OF E-MACROCYCLES WITH RU-BASED OLEFIN METATHESIS CATALYSTS | OXER1, SPR, DHCR7 | ALDH1A1 1159/4885LMNA 4870/4885HSD17B10 117/4885 |
| US-20120122972-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | ALDH1A1 646/4885LMNA 741/4885HSD17B10 229/4885 |
| US-11365183-B2 | Eicosanoid derivatives | FABP3, PTGER3, PTGES3 | ALDH1A1 708/4885LMNA 722/4885HSD17B10 339/4885 |
| US-12622891-B2 | AMP-activated protein kinase activator | PRKAA1, PRKAG1, PRKAB1 | ALDH1A1 1981/4885LMNA 2028/4885HSD17B10 3280/4885 |
| US-20240277657-A1 | NOVEL AMP-ACTIVATED PROTEIN KINASE ACTIVATOR | PRKAG1, PRKAG2, PRKAB1 | ALDH1A1 2638/4885LMNA 3810/4885HSD17B10 3855/4885 |
| US-11407726-B2 | Using stereoretention for the stereoselective formation of e-macrocycles with Ru-based olefin metathesis catalysts | OXER1, SPR, DHCR7 | ALDH1A1 1159/4885LMNA 4870/4885HSD17B10 117/4885 |
| US-20160326128-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | ALDH1A1 710/4885LMNA 730/4885HSD17B10 253/4885 |
| US-20190315701-A1 | NOVEL EICOSANOID DERIVATIVES | FABP3, PTGER3, PTGES3 | ALDH1A1 710/4885LMNA 730/4885HSD17B10 253/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.